A recent poll published by KFF suggests that 66% (two thirds) of adults in the United States take prescription medications. Among these Americans, around 3 in 10 take four or more different prescription drugs regularly. Most Americans are also worried about the cost of medicines for themselves and their families, and about 6 in 10 say they are concerned they may not be able to afford these costs.
Data from the National Center for Health Statistics (NCHS) shows that a significant proportion of Americans take at least one prescription medication, highlighting widespread use. Among these, antithrombotic drugs such as Eliquis (apixaban) and Xarelto (rivaroxaban) are commonly prescribed to prevent serious conditions like blood clots and stroke.
Prescription drug costs in the United States remain high, placing a financial burden on many Americans, with reports from the RAND Corporation showing that prices are significantly higher than in other developed countries, especially for brand-name medications.
Drugs like Eliquis and Xarelto cost more due to patents, fewer alternatives, and complex pricing systems which allow manufacturers to keep prices high over time and explain why these medicines are more expensive in the United States than in other countries..
This guide may help you understand the main factors that affect prescription drug costs, using simple language, trusted data, and practical tips to help you manage costs effectively.
Understanding Eliquis and Xarelto
Eliquis (apixaban) and Xarelto (rivaroxaban) are brand-name direct oral anticoagulants (DOACs), or blood thinners, used to treat and prevent blood clots by blocking Factor Xa, though they differ in dosing, uses, and bleeding risk.
What Are DOACs?
DOACs are newer blood thinners developed as alternatives to warfarin. Eliquis and Xarelto are easier to use, do not require regular blood tests, and have fewer food restrictions, but they are more expensive than older options like warfarin.
How Eliquis and Xarelto Work in the Body?
Eliquis and Xarelto are both factor Xa inhibitors: they block factor Xa, a key clotting protein, which slows the body’s ability to form blood clots.
How they work:
- Eliquis blocks factor Xa, which helps prevent clots from forming and keeps existing clots from getting bigger.
- Xarelto also blocks factor Xa, reducing thrombin production and therefore reducing clot formation.
Both medicines interrupt the clotting cascade at the same step, so the blood is less likely to clot. The main practical difference is not the mechanism, but how they’re dosed and used for specific conditions.
The U.S. Drug Pricing Landscape
The U.S. drug pricing system is complex and depends on private insurers, pharmacy benefit managers (PBMs), and government programs instead of one central system. This structure often leads to higher prices for brand-name drugs like Eliquis and Xarelto compared to other countries.
List Price vs What Americans Pay
Drug companies set a list price, but Americans often pay a different amount. Pharmacy benefit managers (PBMs) negotiate discounts with drug companies, but these savings do not always lower what patients pay. Americans with high-deductible health plans may still pay the full list price, leading to higher out-of-pocket costs.
Medicare Limits on Drug Pricing
For many years, Medicare Part D could not directly negotiate drug prices due to federal policy. This limited government control and allowed manufacturers and PBMs to play a larger role in pricing, which contributed to higher costs .
Core Drivers of High Costs for Eliquis and Xarelto
Eliquis (apixaban) and Xarelto (rivaroxaban) are priced higher due to strong patent protection, limited generic competition, and their clinical benefits. These medications are easier to use than older drugs like warfarin, which adds to their value and cost.
Patent Protection and Delayed Generics
Drug patents give companies exclusive rights for many years. Additional patents on small changes can extend this period, delaying lower-cost generic versions . This keeps Eliquis and Xarelto expensive for a longer time.
Drug Development Costs
Developing new drugs requires major investment (27). According to the Congressional Budget Office (CBO), estimates vary widely, with a 2020 JAMA study placing the median cost at $985 million per drug, while the Tufts Center for the Study of Drug Development estimates $2.6 to $2.8 billion, including clinical failures and time costs.
Marketing and Promotion Costs
Drug companies spend heavily on advertising in the United States. In 2020, about $1.4 billion was spent promoting Eliquis and $623 million on Xarelto. These costs are included in the final price of the medication
Clinical Benefits and Convenience
Eliquis and Xarelto are easier to use than warfarin. They do not require regular blood tests and have fewer interactions with food and other drugs. This convenience and effectiveness contribute to their higher price .
Rising Drug Prices and Real Patient Impact
Prices of medicines like Eliquis and Xarelto have increased steadily over time . These increases are higher than inflation and income growth, mainly due to limited lower-cost options and ongoing patent protection. This also adds to healthcare spending, with billions of dollars spent each year through Medicare.
High costs can make it harder to stay on treatment. Some Americans may delay starting medicine or skip doses because of cost, which can increase health risks such as stroke or blood clots.
Out-of-pocket costs can be a major burden. Americans with high-deductible health plans often pay large amounts before insurance starts to help. This can lead to financial stress, especially for seniors on fixed incomes .
Higher drug prices can affect not only healthcare costs but also daily life, treatment choices, and long-term health.
High U.S. Drug Prices Compared to International Markets
Why Are Drug Prices Higher in the United States?
Prescription drugs in the United States are much more expensive than in other developed countries . For example, Eliquis may cost about $550-$600 per month in the U.S., while in countries like Canada, prices are often around $60-$80. Similar differences are seen in countries such as the United Kingdom, Germany, Australia, and Japan, where governments help control or negotiate drug prices.
Because of these lower prices, some Americans look for options through licensed Canadian pharmacies, including those certified by the Canadian International Pharmacy Association. U.S. rules limit personal importation, but small amounts for personal use have sometimes been allowed under enforcement discretion .
Impact of the Inflation Reduction Act on Drug Prices
Medicare Price Negotiation Changes
In 2022, the Inflation Reduction Act allowed Medicare to negotiate drug prices for the first time. This marked a major change in how prescription drugs are priced in the United States.
New Prices for Eliquis and Xarelto
Eliquis and Xarelto were included in the first group of drugs selected for Medicare negotiation . The Centers for Medicare & Medicaid Services announced new prices starting in 2026.
A 30-day supply of Eliquis will cost about $231, reduced from around $521. Xarelto will cost about $197, down from about $517. These changes represent price reductions of about 56% for Eliquis and 62% for Xarelto.
These lower prices are expected to reduce costs under Medicare Part D. However, the benefit may mainly apply to Medicare enrollees and may not fully apply to those with private insurance.
Broader Implications
This change is expected to influence the broader market. Lower negotiated prices by Medicare can create This policy change may also affect the wider market. Lower Medicare prices can put pressure on drug companies to adjust prices in other plans. Overall, the law is an important step toward improving drug affordability in the United States.
Ways to Save on Eliquis and Xarelto
There are several ways to reduce the cost of Eliquis and Xarelto, but not all options provide consistent or long-term savings. Understanding available programs and pricing differences can help identify a more affordable and sustainable solution.
Patient Assistance Programs and Copay Support
Manufacturer programs, such as copay cards and patient assistance programs (PAPs), are designed to reduce out-of-pocket costs. These programs may lower monthly expenses or, in some cases, provide medication at no cost for eligible individuals. However, eligibility is often limited based on income, insurance status, or other criteria. In addition, copay support may not be permanent and can change over time.
Related post: Are there Alternatives to the Soaring Price of Eliquis?
Insurance Coverage and Formulary Options
Insurance plans can help reduce the cost of these medications, but coverage varies. Some plans may place one medication on a lower-cost tier than the other, affecting out-of-pocket expenses. Even with insurance, high deductibles and copays can result in significant monthly costs. Reviewing formulary options and plan details can help identify potential savings, but it does not always guarantee affordability.
International and Discount Pricing Options
Comparing prices across pharmacies and using discount platforms may help reduce costs to some extent. In addition, some individuals consider licensed Canadian pharmacies that meet recognized safety standards, where prices are often lower. However, access and regulations may vary. While these options can provide savings, they may not always offer a complete long-term solution for managing medication costs.
Related post: Do Canadian Pharmacies Accept US Prescriptions?
Get Eliquis and Xarelto from a Licensed Online Canadian Pharmacy – The Most Reliable Option
Unlike the temporary fixes and eligibility barriers of assistance programs, licensed Canadian pharmacies offer consistently affordable prices due to Canada’s government pricing regulations and controlled markups. This makes them the most reliable long-term solution for U.S. patients seeking affordable medications.
For example, using a trusted prescription referral service such as CanDrugStore.com can help you access medications through Canadian pharmacies at lower prices. You can buy Eliquis for as low as $0.95 per pill. Buy Xarelto for as low as $1.68 per pill. In comparison, typical U.S. prices for similar quantities can exceed $500-$600 per month, depending on dosage and pharmacy. This price difference highlights the potential cost savings available through verified international pharmacy options.
Future Outlook: Generics & Market Competition
Generic competition can help reduce the cost of drugs like Eliquis and Xarelto over time. When patents expire, more companies can make the same medicine, which increases supply and lowers prices.
Generic Entry Timeline
Generic Eliquis is expected around 2028. For Xarelto (rivaroxaban), FDA-approved generics started entering the market between 2025 and 2026. Some patent issues may still affect timing, but these steps move the market toward lower prices.
After generics enter the market, prices often fall quickly. With more competition, costs can drop by 80% to 90% within the first 12 to 18 months, making these medicines more affordable.
Conclusion
The high cost of Eliquis and Xarelto is mainly due to patents, limited competition, complex pricing, and past policy limits. However, recent changes are helping improve affordability. Medicare can now negotiate drug prices, and future generic versions may lower costs further.
Americans can also take steps to reduce expenses. Checking eligibility for assistance programs, comparing pharmacy prices, and speaking with healthcare providers about lower-cost options can help manage out-of-pocket costs.
References
- Aspe, M. (2024). Price changes over time for drugs selected for negotiation. U.S. Department of Health and Human Services. https://aspe.hhs.gov/sites/default/files/documents/3e8abec86039ac0ed674a8c5fac492e3/price-change-over-time-brief.pdf
- Bristol Myers Squibb. (2021, September 30). The BMS-Pfizer Alliance is pleased with the decision by the U.S. Court of Appeals for the Federal Circuit upholding the Eliquis® patents. https://news.bms.com/news/details/2021/The-Bristol-Myers-Squibb-Pfizer-Alliance-is-pleased-with-the-decision-by-the-U.S.-Court-of-Appeals-for-the-Federal-Circuit-upholding-the-Eliquis-Patents/default.aspx
- Canadian International Pharmacy Association. (n.d.). Strict standards ensure safety. https://www.cipa.com/strict-standards-ensure-safety
- Centers for Medicare & Medicaid Services. (2024). Medicare Drug Price Negotiation Program: Negotiated prices for initial price applicability year 2026. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026
- Centers for Medicare & Medicaid Services. (2024). Fact sheet: Negotiated prices – Initial price applicability year 2026. https://www.cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf
- CNN. (2024, February 6). Medicare drug prices: Eliquis, Bernie Sanders. https://edition.cnn.com/2024/02/06/politics/medicare-drug-prices-eliquis-bernie-sanders/index.html
- Commonwealth Fund. (2023, September). The Medicare affordability problem: Cost burdens and the biennial. https://www.commonwealthfund.org/publications/issue-briefs/2023/sep/medicare-affordability-problem-cost-burdens-biennial
- Commonwealth Fund. (2025, November). How drugmakers use the patent process to keep prices high. https://www.commonwealthfund.org/publications/explainer/2025/nov/how-drugmakers-use-patent-process-keep-prices-high
- Dolbow, J. (2023, October 16). How patents contribute to high drug prices. The Regulatory Review. https://www.theregreview.org/2023/10/16/dolbow-how-patents-contribute-to-high-drug-prices/
- Dr. Oracle. (n.d.). What is the mechanism of action of rivaroxaban (Xarelto)? https://www.droracle.ai/articles/123354/what-is-the-mechanism-of-action-of-rivaroxaban-xarelto
- Health Canada. (n.d.). Consultation on the Patented Medicine Regulations. https://www.canada.ca/en/health-canada/programs/consultation-regulations-patented-medicine/document.html
- Healthcare Finance News. (n.d.). The price of two expensive drugs has cost Medicare Part D $46 billion since 2015. https://www.healthcarefinancenews.com/news/price-two-expensive-drugs-has-cost-medicare-part-d-46-billion-2015
- JAMA Network Open. (2024). Comparison of drug prices and availability. https://jamanetworkopen.com/journals/jamanetworkopen/fullarticle/2820562
- Kaiser Family Foundation. (2020). Prices increased faster than inflation for half of all drugs covered by Medicare in 2020. https://www.kff.org/medicare/prices-increased-faster-than-inflation-for-half-of-all-drugs-covered-by-medicare-in-2020/
- Kaiser Family Foundation. (2022). A small number of drugs account for a large share of Medicare Part D spending. https://www.kff.org/medicare/a-small-number-of-drugs-account-for-a-large-share-of-medicare-part-d-spending/
- Kaiser Family Foundation. (2023). Key facts about Medicare drug price negotiation. https://www.kff.org/medicare/key-facts-about-medicare-drug-price-negotiation/
- Kaiser Family Foundation. (2024). What’s the latest on Medicare drug price negotiations? https://www.kff.org/medicare/whats-the-latest-on-medicare-drug-price-negotiations/
- Kaiser Family Foundation. (2026). Public views on prescription drug costs, regulation, affordability, and TrumpRx. https://www.kff.org/public-opinion/public-views-on-prescription-drug-costs-regulation-affordability-and-trumprx/
- Kaiser Family Foundation. (n.d.). FAQs on prescription drug importation. https://www.kff.org/health-costs/faqs-on-prescription-drug-importation/
- Kirley, K., & Qato, D. M. (2019). Cost-related nonadherence to medications among US adults. Circulation, 140(14). https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041974
- Lopes, G. (2021). The impact of new anticoagulants on clinical practice. Journal of Clinical Pharmacy and Therapeutics, 46(2). https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13343
- Managed Healthcare Executive. (n.d.). FDA approves first generics of Xarelto. https://www.managedhealthcareexecutive.com/view/fda-approves-first-generics-of-xarelto
- Medical News Today. (n.d.). Xarelto vs. Eliquis: Differences, similarities, and which is better. https://www.medicalnewstoday.com/articles/drugs-xarelto-vs-eliquis
- Medicare.gov. (n.d.). How drug plans work. https://www.medicare.gov/health-drug-plans/part-d/what-drug-plans-cover/how-drug-plans-work
- Patients For Affordable Drugs. (2022). Eliquis and Xarelto report. https://www.patientsforaffordabledrugs.org/wp-content/uploads/2022/04/Eliquis-and-Xarelto-report.pdf
- Pfizer Oncology Together. (n.d.). Patient assistance program eligibility criteria. https://www.pfizeroncologytogether.com/files/PAP_Eligibility_Criteria.pdf
- Public Broadcasters Group on Health. (2022). Issue Brief: IRA Implementation. https://www.pbgh.org/wp-content/uploads/2022/12/Issue-Brief_IRA-Implementation-1.pdf
- PubMed Central. (2024). Medicare drug pricing negotiations: Assessing constitutional structural limits. https://pmc.ncbi.nlm.nih.gov/articles/PMC10937171/
- PubMed Central. (2024). The clinical and economic impact of direct oral anticoagulants. https://pmc.ncbi.nlm.nih.gov/articles/PMC11482839/
- U.S. Food and Drug Administration. (2019). New evidence linking greater generic competition and lower generic drug prices. https://www.fda.gov/media/133509/download
- U.S. Food and Drug Administration. (n.d.). Generic competition and drug prices. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices
- U.S. Government Accountability Office. (2021). Prescription drugs: Medicare Part B and Part D spending and unit prices. https://www.gao.gov/assets/gao-21-380.pdf
